Section Arrow
Quote
MREO.NASDAQ
- Mereo BioPharma Group plc
Quotes are at least 15-min delayed:2024/12/25 01:49 EST
Last
 3.81
+0.42 (+12.39%)
Day High 
3.88 
Prev. Close
3.39 
1-M High
3.94 
Volume 
1.48M 
Bid
3.63
Ask
3.81
Day Low
3.47 
Open
3.5 
1-M Low
3.11 
Market Cap 
525.94M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.54 
20-SMA 3.55 
50-SMA 3.9 
52-W High 5.02 
52-W Low 2.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.30/-0.37
Enterprise Value
531.24M
Balance Sheet
Book Value Per Share
0.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.06
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed：2024/12/25 01:49 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.